Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Response-Based Radiation Is Effective, Safe in Pediatric High-Risk Hodgkin Lymphoma
December 1st 2020The use of response-based consolidation coupled with radiation therapy was found to be effective and well tolerated, with low failure rates, in pediatric patients with high-risk classical Hodgkin lymphoma.
Read More
EMA Accepts Application for Tepotinib for METex14+ NSCLC
November 30th 2020November 30, 2020 - The European Medicines Agency has validated an application to review tepotinib for the treatment of adult patients with advanced non–small cell lung cancer that harbor MET exon 14 skipping alterations.
Read More
FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma
November 25th 2020The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.
Read More
Selinexor Improves PFS in Advanced Unresectable Dedifferentiated Liposarcoma
November 25th 2020Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.
Read More
SIENDO Trial of Selinexor in Endometrial Cancer Gets Green Light to Continue
November 25th 2020The phase 3 SIENDO study, which is evaluating maintenance selinexor in endometrial cancer, has been recommended by the Data and Safety Monitoring Board to continue as previously planned without the need to add additional patients to the trial or amend the study protocol, following a prespecified interim futility analysis.
Read More
Nivolumab Approved in Europe for Advanced Esophageal Cancer
November 24th 2020November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.
Read More
NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS
November 23rd 2020November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.
Read More
November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.
Read More
Plinabulin/Pegfilgrastim Combo Reduces Rate of Chemotherapy-Induced Neutropenia
November 16th 2020November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.
Read More
Bempegaldesleukin/Nivolumab Combo Upholds Durable Benefit in Metastatic Melanoma
November 13th 2020November 13, 2020 - The combination of bempegaldesleukin and the PD-1 inhibitor nivolumab elicited a confirmed best overall response rate of 53% in efficacy-evaluable patients with metastatic melanoma.
Read More
Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma
November 13th 2020November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.
Read More
Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors
November 12th 2020November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.
Read More
Cosibelimab Elicits Early Activity in NSCLC and Cutaneous Squamous Cell Carcinoma
November 12th 2020November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.
Read More
Cabozantinib/Pembrolizumab Trial Poised to Improve Efficacy, Safety in Advanced Melanoma
November 12th 2020November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.
Read More